tiprankstipranks
Advertisement
Advertisement

ETON Stock Latest News

Eton Pharmaceuticals Maps Aggressive Rare-Disease Growth Path
Company AnnouncementsEton Pharmaceuticals Maps Aggressive Rare-Disease Growth Path
21d ago
ETON
Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright
PremiumThe Fly
Eton Pharmaceuticals price target raised to $52 from $37 at H.C. Wainwright
22d ago
ETON
Eton Pharmaceuticals: Expanding Rare-Disease Portfolio Underpins Attainable Growth Targets and Upside to $52 Price Target
PremiumRatings
Eton Pharmaceuticals: Expanding Rare-Disease Portfolio Underpins Attainable Growth Targets and Upside to $52 Price Target
22d ago
ETON
Eton Pharmaceuticals price target raised to $35 from $30 at Craig-Hallum
PremiumThe Fly
Eton Pharmaceuticals price target raised to $35 from $30 at Craig-Hallum
22d ago
ETON
Eton Pharmaceuticals price target raised to $31 from $26 at B. Riley
PremiumThe Fly
Eton Pharmaceuticals price target raised to $31 from $26 at B. Riley
22d ago
ETON
Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year
PremiumThe FlyEton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year
23d ago
ETON
Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M
Premium
The Fly
Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M
23d ago
ETON
Is ETON a Buy, Before Earnings?
Premium
Pre-Earnings
Is ETON a Buy, Before Earnings?
25d ago
ETON
Eton Pharmaceuticals participates in a conference call with Craig-Hallum
PremiumThe Fly
Eton Pharmaceuticals participates in a conference call with Craig-Hallum
30d ago
ETON
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum
PremiumThe Fly
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum
1M ago
ETON
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
PremiumCompany Announcements
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
1M ago
8K
ETON
Eton in-licenses U.S. commercialization rights to HEMANGEOL from Pierre Fabre
PremiumThe Fly
Eton in-licenses U.S. commercialization rights to HEMANGEOL from Pierre Fabre
1M ago
ETON
Eton Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright
PremiumThe FlyEton Pharmaceuticals price target raised to $37 from $35 at H.C. Wainwright
1M ago
ETON
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy
Premium
Company Announcements
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy
1M ago
8K
ETON
Eton Pharmaceuticals trading resumes
Premium
The Fly
Eton Pharmaceuticals trading resumes
1M ago
ETON
Eton Pharmaceuticals announces FDA approval for Desmoda Oral Solution
PremiumThe Fly
Eton Pharmaceuticals announces FDA approval for Desmoda Oral Solution
1M ago
ETON
Eton Pharmaceuticals trading halted, news pending
PremiumThe Fly
Eton Pharmaceuticals trading halted, news pending
1M ago
ETON
Eton Pharmaceuticals Licenses U.S. Rights to Ultra-Rare Drug
PremiumCompany Announcements
Eton Pharmaceuticals Licenses U.S. Rights to Ultra-Rare Drug
2M ago
8K
ETON
Eton licenses U.S. marketing rights to ultra-rare disease product candidate
PremiumThe Fly
Eton licenses U.S. marketing rights to ultra-rare disease product candidate
2M ago
ETON
Eton Pharmaceuticals: Promising Growth Trajectory with Projected Revenue Surge and Strategic Developments
PremiumRatingsEton Pharmaceuticals: Promising Growth Trajectory with Projected Revenue Surge and Strategic Developments
4M ago
ETON
Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference
Premium
Company Announcements
Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference
4M ago
8K
ETON
Eton Pharmaceuticals management to meet with B. Riley
Premium
The Fly
Eton Pharmaceuticals management to meet with B. Riley
4M ago
ETON

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >